Phase 2 study of neratinib for adolescents and adults with neurofibromatosis 2 and progressive NF2-related neoplasms: a sub-study of the INTUITT-NF2 platform-basket trial (NCT04374305)
Latest Information Update: 20 Jul 2021
At a glance
- Drugs Neratinib (Primary)
- Indications Neurofibromatosis 2
- Focus Therapeutic Use
- 20 Jul 2021 New trial record
- 15 Jul 2021 According to a National Comprehensive Cancer Network media release, this study is funded by the National Comprehensive Cancer Network (NCCN) Oncology Research Program (ORP). This study will commence in late 2021 and take place over two year.